Elastrin Therapeutics, a Greenville, SC-based biotechnology company, raised $10M in funding.
The round was led by Kizoo Technology Capital, with participation from Starbloom Capital and SC Launch.
The company intends to use the funds to expand operations and its development efforts.
Founded in 2018 as a spinout from Clemson University where the technology was first developed by Dr. Naren Vyavahare over a 20-year period, and led by CEO Matthias Breugelmans, Elastrin Therapeutics is a biotech company developing therapies to reverse cardiovascular disease. The lead asset ELT-001 is an EDTA-loaded nanoparticle conjugated with a proprietary monoclonal antibody for the treatment of vascular calcification.